MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 18, 2007; DOI: 10.1124/mol.107.043125


0026-895X/08/7303-769-777$20.00
Mol Pharmacol 73:769-777, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.043125v1
73/3/769    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monteiro, P.
Right arrow Articles by Fardel, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monteiro, P.
Right arrow Articles by Fardel, O.

Dioxin-Mediated Up-Regulation of Aryl Hydrocarbon Receptor Target Genes Is Dependent on the Calcium/Calmodulin/CaMKI{alpha} Pathway

Patricia Monteiro, David Gilot, Eric Le Ferrec, Claudine Rauch, Dominique Lagadic-Gossmann, and Olivier Fardel

Institut National de la Santé et de la Recherche Médicale (INSERM U620), Equipe labellisée par la Ligue Nationale contre le Cancer (P.M., D.G., E.L., C.R., D.L.G., O.F.) and Université de Rennes 1, IFR140, Rennes, France (P.M, D.G., E.L., C.R., D.L.G., O.F.); and Department HITC, Hôpital Pontchaillou, CHU, Rennes, France (O.F.)

Regulation of genes targeted by the ligand-activated aryl hydrocarbon receptor (AhR) has been shown to be controlled by calcium (Ca2+) changes induced by AhR agonists such as the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The present study was designed to characterize this link between Ca2+ and the AhR pathway. We report that fast elevation of intracellular Ca2+ in TCDD-exposed mammary MCF-7 cells was associated with transient enhanced activity of the Ca2+/calmodulin (CaM)-dependent protein kinase (CaMK) pathway. Chemical inhibition of this pathway using the CaM antagonist W7 or the CaMK inhibitor KN-93 strongly reduced TCDD-mediated induction of the AhR target gene CYP1A1. Small interfering RNA (siRNA)-mediated knockdown expression of CaMKI{alpha}, one of the CaMK isoforms, similarly prevented CYP1A1 up-regulation. Both KN-93 and siRNA targeting CaMKI{alpha} were found to abolish TCDD-mediated activation of CYP1A1 promoter and TCDD-triggered nuclear import of AhR, a crucial step of the AhR signaling pathway. TCDD-mediated inductions of various AhR targets, such as the drug metabolizing CYP1B1, the cytokine interleukin-1β, the chemokines interleukin-8 and CCL1, the adhesion molecule β7 integrin, and the AhR repressor, were also prevented by KN-93 in human macrophages. Taken together, these data identified the Ca2+/CaM/CaMKI{alpha} pathway as an important contributing factor to AhR-mediated genomic response.


Received November 5, 2007; accepted December 17, 2007

Address correspondence to: David Gilot, INSERM U620, Université de Rennes1, Faculté des Sciences Pharmaceutiques et Biologiques, IFR140, 2 Avenue du Professeur Léon Bernard, 35043 Rennes Cedex, France. E-mail: david.gilot{at}rennes.inserm.fr




This article has been cited by other articles:


Home page
International Journal of ToxicologyHome page
Y.-H. Kim, Y.-J. Shim, Y.-J. Shin, D. Sul, E. Lee, and B.-H. Min
2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Induces Calcium Influx Through T-type Calcium Channel and Enhances Lysosomal Exocytosis and Insulin Secretion in INS-1 Cells
International Journal of Toxicology, May 1, 2009; 28(3): 151 - 161.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. Monteiro, D. Gilot, S. Langouet, and O. Fardel
Activation of the Aryl Hydrocarbon Receptor by the Calcium/Calmodulin-Dependent Protein Kinase Kinase Inhibitor 7-Oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic Acid (STO-609)
Drug Metab. Dispos., December 1, 2008; 36(12): 2556 - 2563.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics